Ligand Pharmaceuticals
LGND
192 hedge funds and large institutions have $1.3B invested in Ligand Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 85 increasing their positions, 61 reducing their positions, and 22 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 61
36% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 22
4% more funds holding
Funds holding: 184 → 192 (+8)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
8% less capital invested
Capital invested by funds: $1.4B → $1.3B (-$106M)
40% less call options, than puts
Call options by funds: $8.25M | Put options by funds: $13.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Conestoga Capital Advisors
Wayne,
Pennsylvania
|
+$15.9M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
+$11M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$9.79M |
| 4 |
NAM
Nichols Asset Management
Sudbury,
Massachusetts
|
+$8.48M |
| 5 |
Goldman Sachs
New York
|
+$4.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$15.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$13.2M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$10M |
| 4 |
CM
Castleark Management
Chicago,
Illinois
|
-$8.81M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$7.67M |
LGND Hedge Fund Activity: Q2 2014 in Review
192 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2014, worth a combined $1.3B — down 7.6% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LGND positions and 22 closed out — a net gain of 8 holders — while 85 added to existing stakes and 61 trimmed.
The largest buyer was Conestoga Capital Advisors, opening a new position worth an estimated $15.9M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $15.7M.
- 192 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2014, up from 184 in Q1 2014.
- Funds reported $1.3B of Ligand Pharmaceuticals stock for Q2 2014, down 7.6% quarter-over-quarter.
- 30 funds opened new Ligand Pharmaceuticals positions in Q2 2014 and 22 closed out, a net change of +8 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2014 was Conestoga Capital Advisors, an estimated $15.9M added.
- The largest Ligand Pharmaceuticals seller in Q2 2014 was Gilder Gagnon Howe & Co, an estimated $15.7M sold.
Based on aggregated 13F filings for Q2 2014.